PepGen PEPG
NASDAQ PEPG
$3.11 -0.07 (-2.20%)
As of: Sep 4, 2026 · 3:59 PM EDT

PepGen (PEPG) Income towards Parent Company (2021 - 2026)

PepGen (PEPG) posted Income towards Parent Company of -$17.8 million for Q1 2026, up 2.89% sequentially from -$18.3 million in Q4 2025, and up 41.19% YoY from -$12.6 million in Q1 2025.

Analysis

PepGen (PEPG) Income towards Parent Company (2021 - 2026) Analysis & Trends

PepGen has reported Income towards Parent Company for 6 years, with the latest figure at -$17.8 million in Q1 2026.

  • Quarterly Income towards Parent Company rose 41.19% year-over-year to -$17.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$77.2 million (up 24.92% YoY) and the FY2025 annual result came in at -$89.7 million, changed 0.36% from the prior year.
  • Income towards Parent Company improved to -$17.8 million in Q1 2026 per PEPG's latest filing, from -$18.3 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at -$16.3 million in Q1 2023 and troughed at -$46.3 million in Q4 2022.
  • A 5-year average of -$22.2 million and a median of -$19.4 million in 2023 frame the typical range for Income towards Parent Company.
  • The sharpest annual moves came in 2022 and 2023: Income towards Parent Company plunged 4709.24% in 2022, then jumped 58.06% in 2023.
  • Over 5 years, Income towards Parent Company stood at -$46.3 million in 2022, then surged by 58.06% to -$19.4 million in 2023, then decreased by 17.7% to -$22.9 million in 2024, then grew by 19.98% to -$18.3 million in 2025, then gained by 2.89% to -$17.8 million in 2026.
  • According to Business Quant data, Income towards Parent Company over the past three periods registered -$17.8 million, -$18.3 million, and -$18.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn
5 Revolution Medicines 44.33 Bn 44.33 Bn -
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn -
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn
10 PepGen 217.99 Mn 217.99 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -17.81 Mn
Mar 31, 2026 -17.76 Mn
Dec 31, 2025 -18.29 Mn
Sep 30, 2025 -18.03 Mn
Jun 30, 2025 -23.09 Mn
Mar 31, 2025 -30.20 Mn
Dec 31, 2024 -22.86 Mn
Sep 30, 2024 -21.38 Mn
Jun 30, 2024 -28.34 Mn
Mar 31, 2024 -18.02 Mn
Dec 31, 2023 -19.42 Mn
Sep 30, 2023 -23.29 Mn
Jun 30, 2023 -19.52 Mn
Mar 31, 2023 -16.32 Mn
Dec 31, 2022 -46.31 Mn
Sep 30, 2022 -18.61 Mn
Jun 30, 2022 -17.32 Mn
Mar 31, 2022 -18.25 Mn
Dec 31, 2021 -7.14 Mn
Sep 30, 2021 -8.11 Mn